Inhibitex

Hepatitis C Remains A Hot Play
Seeking Alpha
Mon, 02/27/12 - 12:01 pm
hepatitis C
Bristol-Myers Squibb
Novartis
Gilead
Inhibitex
Merck
Vertex
Pharmasset
Enanta
Drugmakers Seek Deals to Gain Share of Future Hepatitis C Combination Pill
Bloomberg
Wed, 02/15/12 - 08:55 am
M&A
Inhibitex
Indenix
hepatitis C
Bristol-Myers Squibb
Achillion
Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Inhibitex, Inc.
Yahoo
Mon, 02/13/12 - 10:26 am
Inhibitex
Bristol-Myers Squibb
M&A
Easing The Pain: Why Investment In Bio-Pharma Is A Worthy Cause
Seeking Alpha
Wed, 02/1/12 - 12:19 pm
Bristol-Myers Squibb
Ariad Pharmaceuticals
Inhibitex
Vertex Pharmaceuticals
Spectrum Pharmaceuticals
MannKind
Biotech Equities Continue To Benefit From Discoveries And Acquisitions In 2012
Seeking Alpha
Fri, 01/27/12 - 11:08 am
Alexion
Amgen
Ariad
Biogen Idec
Bristol-Myers Squibb
Celgene
Gilead
Illumina
Inhibitex
Vertex Pharmaceuticals
Second confirmed bidder for Inhibitex bodes well for Idenix, says Wedbush
Yahoo/Fly on the Wall
Wed, 01/18/12 - 10:22 am
M&A
Bristol-Myers Squibb
Inhibitex
Inhibitex Auction Shows Battle for Hepatitis Drugs
Minyanville
Wed, 01/18/12 - 09:49 am
hepatitis
hepatitis C
Inhibitex
Bristol-Myers Squibb
Why Big Pharma Doesn't Really Need (Or Even Want) A Pipeline
Seeking Alpha
Tue, 01/17/12 - 06:48 pm
Adolor
Alexion
Amgen
Cubist Pharmaceuticals
AstraZeneca
Bristol-Myers Squibb
Inhibitex
Merck
Pfizer
Stryker
Bristol-Myers Raised Inhibitex Offer 30%
Bloomberg
Sat, 01/14/12 - 11:40 am
Bristol-Myers Squibb
Inhibitex
M&A
CEO Gaffe of the Week: Bristol-Myers Squibb
Motley Fool
Sat, 01/14/12 - 11:35 am
Bristol-Myers Squibb
Inhibitex
M&A
Analyzing 5 Biotech Stocks And Their Takeover Potential
Seeking Alpha
Fri, 01/13/12 - 10:33 am
Abbott Laboratories
Achillion
Alexion
Bristol-Myers Squibb
Gilead
GSK
Human Genome Sciences
Indenix
Inhibitex
JNJ
Pfizer
Vertex
Pharmasset
Bristol-Myers Squibb Begins Tender Offer to Acquire Inhibitex, Inc.
Yahoo
Fri, 01/13/12 - 09:27 am
Inhibitex
tender offer
M&A
Bristol-Myers Squibb
Inhibitex Shareholders Sue Over Bristol’s $2.5 Billion Offer
Bloomberg
Thu, 01/12/12 - 10:07 pm
shareholders
M&A
Inhibitex
Bristol-Myers Squibb
3 Reasons Hep C Premiums Might Not Last
Motley Fool
Tue, 01/10/12 - 09:50 am
hepatitis C
Anadys
Roche
Gilead
Pharmasset
Bristol-Myers Squibb
Inhibitex
A White Hot Hep C Market: What The Wags Say
Pharmalot
Mon, 01/9/12 - 01:24 pm
hepatitis C
Inhibitex
Bristol-Myers Squibb
Gilead
Pharmasset
M&A
JPM kicks off with fevered focus on the next big biotech deal
Fierce Biotech
Mon, 01/9/12 - 10:42 am
JPMorgan
biotech
M&A
Inhibitex
Bristol-Myers Squibb
Bristol’s Buy of Inhibitex for Hepatitis Drug Won’t Be Last
Bloomberg
Mon, 01/9/12 - 10:12 am
Bristol-Myers Squibb
M&A
Inhibitex
hepatitis C
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Yahoo/AP
Mon, 01/9/12 - 09:57 am
hepatitis C
Bristol-Myers Squibb
M&A
Inhibitex
Gilead
Pharmasset
S&P: Bristol-Myers announcement will not affect rating
Reuters
Mon, 01/9/12 - 09:53 am
Bristol-Myers Squibb
M&A
Inhibitex
Bristol-Myers to Acquire Inhibitex for $2.5 Billion
NY Times, NY
Mon, 01/9/12 - 09:15 am
Bristol-Myers Squibb
Inhibitex
M&A

Pages